Subscribe to email alerts
Nutrition and dietetics
Letters were sent about daclizumab beta (Zinbryta▼), alteplase (Actilyse), Esmya (ulipristal acetate), and Xofigo▼ (radium-223-dichloride).
Alerts were recently issued about Novaline haemodialysis bloodlines used with Baxter/Gambro haemodialysis machines and Alaris and Asena enteral syringe pumps
Report to the Yellow Card Scheme suspected adverse reactions associated with medicines taken during pregnancy experienced by women or the baby or child.
With the exception of medicines containing zidovudine, stavudine, or didanosine, product information will no longer include warnings on fat redistribution or lactic acidosis.
The licence-holder of ferumoxytol has voluntarily withdrawn it from the UK market for commercial reasons.
The new module helps clinicians understand how to identify, manage and avoid side effects when using corticosteroids.
Since November 2014, letters were sent regarding vismodegib (Erivedge ▼), chlorhexidine solutions, carbocisteine oral liquid (Mucodyne Paediatric 125mg/5ml), regadenoson (Rapiscan), a parenteral nutrition emulsion (Triomel), and telavancin (Vibativ▼).
New recommendations are being introduced to minimise the risk of serious hypersensitivity reactions with ferumoxytol.
People now need to have a medical assessment before taking domperidone to determine if it is suitable for them due to the risk of cardiac side effects.
After every use, an ambulance should be called even if symptoms are improving, the individual should lie down with legs raised and, if at all possible, should not be left alone.
Indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use.
Initiate orlistat treatment only after careful consideration of the possible impact on efficacy of antiretroviral HIV medicines.
Clarification of advice on new recommendations regarding initial test dose.
New strengthened recommendations to manage and minimise risk.
Do not use in children aged 16 years or less, except in specialist settings under expert medical supervision.
Healthcare professionals should be aware that these capsules contain potential allergens.
Studies of cardiovascular risk don’t support prescribing changes.
A recent Europe-wide review of the safety information for alli has led to a number of updates, which bring the product information in line with that for Xenical.
Evidence indicates risks outweigh benefits.
To avoid the risk of air embolism, these products should not be infused under pressure.
Rare occurrence of serious allergic reactions should not preclude use of parenteral thiamine in patients who need treatment by this route of administration.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.